Intravitreal dexamethasone implant shows promise in addressing persistent neovascular AMD

The addition of intravitreal dexamethasone implant (Dex; Ozurdex) to the treatment regimen of patients with neovascular age-related macular degeneration (nAMD) with persistent disease activity and high treatment demand resulted in a significant and sustained increase in treatment intervals, according to a study. Despite the longer treatment intervals, central retinal thickness...